What effect did ARNI show in reducing cardiovascular death compared to ACE inhibitor alone?

ARNI, or angiotensin receptor-neprilysin inhibitor, has been shown in clinical studies, particularly in the PARADIGM-HF trial, to significantly improve outcomes in patients with heart failure compared to traditional treatments like ACE inhibitors. Specifically, this trial demonstrated that ARNI reduced the risk of cardiovascular death by approximately 20% when compared to the use of an ACE inhibitor alone.

The 20% reduction in cardiovascular mortality is attributed to the dual-action of ARNI, as it not only inhibits the angiotensin receptor but also modulates neprilysin, leading to increased levels of natriuretic peptides and improved cardiac function. This effect is particularly beneficial for heart failure patients, as it helps alleviate the burden of heart failure symptoms and decreases mortality rates associated with cardiovascular issues.

Recognizing this specific percentage is crucial for understanding the significant impact ARNI therapy has on clinical outcomes for heart failure patients and reinforces the importance of adopting evidence-based medication regimens in managing heart failure effectively.